<DOC>
	<DOC>NCT01917630</DOC>
	<brief_summary>To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Ages 18 to 80 years Physician diagnosed celiac disease Adherence to a glutenfree diet Experiencing symptoms of celiac disease over a 1month period Willing to take study medication for 12 weeks Willing to comply with all study procedures Sign informed consent Active inflammatory bowel disease Active dermatitis herpetiformis Use of certain specific medications prior to entry History of alcohol or illicit drug abuse in previous 6 months Pregnant or lactating Received any experimental drug within 30 days of enrollment Uncontrolled chronic disease or condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Celiac disease</keyword>
	<keyword>Gluten-free diet</keyword>
	<keyword>Coeliac disease</keyword>
	<keyword>Celiac sprue</keyword>
</DOC>